Cerevel Therapeutics Names Sulzberger to its Board of Directors
6 November 2019 - - US-based neuroscience disease treatments developer Cerevel Therapeutics has added Gabrielle Sulzberger to serve as an independent member of its board of directors, the company said.
Sulzberger is the former chairperson of the board of Whole Foods and an accomplished financial services professional with over 30 years of experience in both private equity and as a chief financial officer across a broad range of industries, including consumer goods, retail, financial services and healthcare.
She also possesses extensive corporate governance expertise, having served on the boards of several publicly-traded and privately-held companies, with particular expertise in mergers and acquisitions, risk assessment, as well as engagement with shareholder activists.
Sulzberger currently serves as general partner of Rustic Canyon/Fontis Partners, a position she has held since 2007.
Prior to joining RC/Fontis, Sulzberger served as chief financial officer of several public and private companies, including Gluecode Software, a venture-backed open source software company which was sold to IBM, and Crown Services, a California-based consolidation of commercial contractors.
Until August of 2017, Sulzberger served as chairperson of the board of Whole Foods and previously spent 13 years as chairperson of Whole Foods' audit committee.
She currently serves on the boards of MasterCard, Brixmor Property Group, where she chairs the governance committee, and two private-equity backed companies: Acorns and True Food Kitchen, where she also serves as chairperson.
Sulzberger has also served on four other public company boards: Teva Pharmaceuticals, Stage Stores, IndyMac Bank, and Bright Horizons, as well as numerous private company boards.
Sulzberger is a Trustee of the Ford Foundation. She also serves on the boards of the Women Corporate Directors Foundation, the National Association of Corporate director's Audit Advisory Council, Trinity Church Wall Street and is a Henry Crown Fellow of the Aspen Institute.
In 2014 she was named a "Top 100 director" by the National Association of Corporate directors.
Sulzberger earned her B.A. from the Woodrow Wilson School of Princeton University. She received her M.B.A. from Harvard Business School and J.D. from Harvard Law School and is a member of the Massachusetts Bar.
Cerevel Therapeutics has a pipeline comprising four clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson's, epilepsy, schizophrenia and substance use disorders.
Headquartered in Boston, Cerevel Therapeutics is advancing its current research and development programmes while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.